Contrast-enhanced breast MRI is the most sensitive and accurate imaging modality for the local-regional staging of breast cancer.
and/or radiation, possibly followed by chest wall resection. However, a tumor invading the pectoral muscle may only require partial or complete resection of the muscle. 1 Infi ltrative or mass-like contrast enhancement is the only reliable MRI fi nding to predict invasion of the pectoral muscles and chest wall.
Nipple and Skin Involvement
Malignant involvement of the skin may be seen in infl ammatory breast carcinoma resulting from tumor micrometastases within dermal lymphatics; or, in the case of locally advanced breast cancer, from direct skin invasion by an underlying tumor. Skin thickening and enhancement are signs of skin involvement, often contiguous with an underlying malignancy. Unilateral nipple enhancement on breast MRI is suggestive of malignant nipple involvement,
The continuing education activity in Contemporary Diagnostic Radiology is intended for radiologists. supraclavicular nodes, most of the regional nodes, including ipsilateral axillary (levels I-III), internal mammary, and intramammary nodes, are in the fi eld of view on breast MRI ( Figure 7 ). Features suggesting a nodal metastasis include loss of the fatty hilum, increased cortical thickness (>3 mm), focal cortical thickening, irregular margins, edema surrounding the node, and asymmetry of these features compared with the opposite axilla. Any visualized internal mammary node, especially when larger than 5 mm, should be regarded as suspicious for metastasis. 1 Except for the supraclavicular nodes, most of the regional breast nodes are in the fi eld of view on breast MRI.
especially when the nipple is contiguous with the underlying tumor ( Figure 5 ). Involvement of the nipple by underlying malignancy is an important factor in surgical planning, as it requires resection of the nipple-areola complex, usually with mastectomy. 1 Unilateral nipple enhancement on breast MRI is suggestive of malignant nipple involvement, especially when the nipple is contiguous with the underlying tumor.
Regional Lymph Nodes
The detection of regional lymph node metastases is an important part of breast cancer staging. Except for the This left ML mammographic view shows a large, ill-defi ned focal asymmetry at the 12:00 location (between arrows), corresponding to the palpable mass. The tissue marker and overlying skin changes are related to a recent percutaneous core biopsy. A sonogram revealed 3 adjacent ducts distended with hypoechoic tissue or debris (not shown). B: Breast MRI was performed because of the discrepancy of tumor size among the clinical examination, mammography, and ultrasound. This sagittal, postcontrast, fat-saturated, T1-weighted MIP MR image shows a large area of clumped nonmass enhancement in the central upper breast (between arrows), with rapid and mixed, plateau/washout kinetics (not shown). Simple mastectomy confi rmed extensive DCIS without an invasive focus.
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Subsets of Patients Likely to Benefi t From Preoperative Breast MRI
The subsets of patients most likely to benefi t from preoperative breast MRI are:
• Patients with dense breast tissue, because tumor visualization in these patients tends to be hindered on mammography;
• Patients with invasive lobular carcinoma, because these tumors tend to be multiple and bilateral; • Patients with posterior breast cancer, for detection of pectoral muscles and chest wall invasion; • Patients planning to undergo partial breast irradiation, because patients with multiple tumors are not fully treated with partial breast irradiation and, therefore, are not appropriate candidates for this type of therapy; and • High-risk patients, such as patients with genetic alterations (BRCA1 and BRCA2 mutations) or a history of mantle chest radiation because these patients are at high risk for multiple and bilateral breast cancers. 1 Other clinical scenarios for which preoperative breast MRI is useful include: 
Literature Against Preoperative Breast MRI
Based on the previous discussion, the anticipated clinical benefi ts of preoperative breast MRI include decreased positive surgical margins and reexcision rates; better stratifi cation of patients for breast conserving therapy (BCT) versus mastectomy; decreased local recurrence rates by resecting otherwise occult multifocal or multicentric tumors; and decreased metachronous contralateral cancer rates by simultaneous detection and treatment of contralateral tumors. However, the clinical outcome studies evaluating the actual overall benefi t of MRI show confl icting results. Controversy over the use of preoperative breast MRI has focused on the issues of delay in defi nitive therapy, reexcision rates, mastectomy rates, and long-term survival impact. 3 
Delay in Defi nitive Therapy
Two studies have shown treatment delays of 17 to 22.4 days in the group of patients undergoing preoperative breast MRI. However, Hollingsworth and Stough 4 asserted that all of their patients completed MRI work-up before the surgeon's fi rst open clinic date; hence there was no delay in treatment. The potential delay is attributed to the detection of additional lesions by MRI, necessitating additional imaging and biopsy. Although the delay is unlikely to affect patient survival, it is felt to contribute to the cost of care and patient anxiety. To minimize delay, it is imperative that facilities that offer breast MRI have the commitment and capability to complete evaluation and biopsy of MRI-detected lesions promptly. If not, they should have decreased reexcision rates in patients with preoperative breast MRI, while studies 7 to 11 showed no benefi t in the MRI group. Many of these retrospective studies undoubtedly have patient selection bias by performing more MRIs on patients at higher risk for positive margins. MRI may have reduced the reexcision rates in these patients to the same level as the lower risk (no MRI) group, therefore an established referral arrangement with an experienced breast center to provide these services.
Confl icting Data on Reexcision Rates
There are confl icting results among the outcome studies on reexcision rates with and without preoperative breast MRI ( Table 1) . As shown in Table 1 , studies 1 to 6 showed 
Survival Impact
Currently, the impact of preoperative MRI on survival after BCT is uncertain because of the lack of long-term outcome data. Three retrospective studies of the impact of MRI on the local recurrence rate, which may infl uence longterm survival, showed confl icting results. 8 Because of the current low rates of local recurrence after BCT, and low contralateral cancer rates, opponents of preoperative MRI question the benefit of finding additional cancer foci, because these foci should be treated effectively with whole breast radiation and systemic therapy, and may be clinically insignificant. 3 However, the International Breast MRI Consortium 6883 study showed that cancers found only on MRI were similar in size and histology to cancers detected on mammography, but had a higher likelihood of being higher grade. Hence there is no basis to assume that the additional MRI-detected cancers are biologically inert, are clinically irrelevant, or will be treated adequately by standard therapies used in BCT. 8 Furthermore, the increasing use of partial breast radiation places even greater signifi cance on these additional cancers, which will remain potentially untreated. 4 
Conclusion
This CME activity emphasizes that MRI is the most accurate modality for local-regional staging of breast cancer. Findings of multifocal, multicentric, and contralateral tumors help guide surgical planning and decisions on adjuvant therapy. MRI is benefi cial in a subset of women, particularly those with large tumors, dense breast tissue, or invasive lobular cancer. Many studies show that preoperative breast MRI reduces reexcision rates, although no increased survival benefi t has been proven. The clinical outcome studies to date have limitations and are not generalizable to modern breast MRI practice. A well-designed prospective randomized controlled trial on the short-and long-term benefi ts of preoperative breast MRI is needed and is currently under development by the American College of Radiology Imaging Network (ACRIN).
masking the benefi t of MRI. It is important to note that studies 3, 4, and 11 showed consistent reduction of reexcision rates in patients with invasive lobular carcinoma (ILC) undergoing preoperative breast MRI.
The recently published Comparative Effectiveness of MRI in Breast Cancer (COMICE) and MR Mammography of Nonpalpable Breast Tumors (MONET) trials are prospective studies (studies 12 and 13, respectively; Table 1 ). The COMICE trial found no difference in reexcision rates between patients with or without MRI. 5 This trial, conducted in the United Kingdom, involved 45 breast centers of widely varied expertise in breast MRI. Because the UK national health policy mandates reoperation rates for positive margins to be under10%, the very wide excisions routinely performed in the UK during lumpectomy could have negated the benefi t of MRI. The MONET trial found a paradoxical increase in reexcision rates in patients with MRI (34% MRI vs. 12% no MRI). 6 This trial focused on nonpalpable breast cancers, resulting in 60% of the lesions being ductal carcinoma in situ (DCIS) identifi ed as microcalcifi cations only, which is not as well evaluated by MRI as invasive cancer. The mean volume of excised tissue in the MRI group was smaller than in the non-MRI group (69.1 cm 3 vs. 90.2 cm 3 ). It was even smaller in patients with DCIS and a negative MRI (40.3 cm 3 ). These fi ndings are the most likely explanation for the paradoxically higher rates of positive margins and reexcision. 6 
Mastectomy Rate
MRI has been criticized for overestimation of tumors leading to pathologically unjustifi ed mastectomies or wider excisions. A meta-analysis of 19 studies on the impact of MRI on surgical planning showed a conversion rate of 1.1% from BCT to mastectomy and a conversion rate of 5.5% to more extensive excision because of false-positive MRI fi ndings. 2 These pathologically unjustifi ed surgeries are avoidable in modern practice with the availability of MRI-guided biopsy. It is important that any change in surgical management should be based on biopsy proof of more extensive disease, not just suspicious imaging fi ndings. The analysis showed pathologically justifi ed conversions from BCT to mastectomy in 8.1% of cases, which roughly equals the 10-year local recurrence rate. It is possible that MRI selects the women destined for recurrence and converts their treatment to mastectomy at the time of initial surgery.
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